We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-0.77%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.55B
AUM Growth
-$472M
(-5.9%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
20.77%
Holding
863
New
59
Increased
344
Reduced
256
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$25.4M |
| 2 |
AbbVie
ABBV
|
+$21.9M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$19.2M |
| 4 |
Waste Management
WM
|
+$19M |
| 5 |
Gilead Sciences
GILD
|
+$17.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$70.2M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
+$45.8M |
| 3 |
Biogen
BIIB
|
+$43.3M |
| 4 |
Meta Platforms (Facebook)
META
|
+$24.8M |
| 5 |
Amgen
AMGN
|
+$21.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.81% |
| 2 | Technology | 18.27% |
| 3 | Financials | 10.05% |
| 4 | Consumer Discretionary | 9.39% |
| 5 | Communication Services | 7.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Microsoft
MSFT
$2.95T
| $254M | 3.37% |
1,830,407
+84,574
| +5% | +$11.6M |
|
|
2
Amgen
AMGN
$198B
| $176M | 2.33% |
908,380
-113,225
| -11% | -$21.7M |
|
3
Vertex Pharmaceuticals
VRTX
$122B
| $158M | 2.09% |
930,999
-9,507
| -1% | -$1.68M |
|
4
Alphabet (Google) Class A
GOOGL
$4.24T
| $157M | 2.08% |
2,572,560
-221,480
| -8% | -$13.1M |
|
5
Apple
AAPL
$4.81T
| $148M | 1.96% |
2,644,872
-36,656
| -1% | -$1.92M |
|
|
6
Gilead Sciences
GILD
$165B
| $142M | 1.89% |
2,246,895
+270,870
| +14% | +$17.7M |
|
7
Amazon
AMZN
$2.66T
| $138M | 1.83% |
1,591,420
+10,800
| +0.7% | +$1M |
|
8
Bristol-Myers Squibb
BMY
$124B
| $133M | 1.76% |
2,621,006
+193,121
| +8% | +$9.08M |
|
9
Merck
MRK
$312B
| $132M | 1.75% |
1,647,324
-110,106
| -6% | -$8.82M |
|
10
Alibaba
BABA
$283B
| $129M | 1.7% |
768,643
+22,672
| +3% | +$3.9M |
|
11
Regeneron Pharmaceuticals
REGN
$70.5B
| $114M | 1.52% |
412,174
+26,433
| +7% | +$7.82M |
|
12
Procter & Gamble
PG
$345B
| $112M | 1.48% |
898,238
-55,653
| -6% | -$6.58M |
|
|
13
Biogen
BIIB
$29.5B
| $102M | 1.35% |
438,589
-186,131
| -30% | -$43.3M |
|
|
14
Meta Platforms (Facebook)
META
$1.63T
| $95.7M | 1.27% |
537,263
-130,733
| -20% | -$24.8M |
|
15
Illumina
ILMN
$27.9B
| $79.7M | 1.06% |
269,381
+12,914
| +5% | +$3.81M |
|
16
Cisco
CSCO
$442B
| $73.3M | 0.97% |
1,483,896
+258,042
| +21% | +$13.4M |
|
17
Visa
V
$677B
| $67.4M | 0.89% |
391,559
-24,332
| -6% | -$4.33M |
|
|
18
AbbVie
ABBV
$448B
| $65.4M | 0.87% |
864,113
+318,994
| +59% | +$21.9M |
|
19
Walt Disney
DIS
$167B
| $62.6M | 0.83% |
480,584
-10,893
| -2% | -$1.51M |
|
|
ALXN
20
DELISTED
Alexion Pharmaceuticals
ALXN
| $61.9M | 0.82% |
631,766
+66,533
| +12% | +$7.5M |
|
21
TSMC
TSM
$2.2T
| $59.1M | 0.78% |
1,270,878
+264,585
| +26% | +$11.3M |
|
22
Abbott
ABT
$174B
| $58.3M | 0.77% |
697,064
-18,753
| -3% | -$1.59M |
|
23
PepsiCo
PEP
$184B
| $54.3M | 0.72% |
396,349
-4,222
| -1% | -$561K |
|
24
Johnson & Johnson
JNJ
$599B
| $53.9M | 0.71% |
416,493
+3,961
| +1% | +$522K |
|
25
PayPal
PYPL
$49.3B
| $51.7M | 0.69% |
499,099
+127,336
| +34% | +$14M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2019 Portfolio in Review
As of Q3 2019, Candriam SCA held 863 positions worth $7.55B, down 5.9% from $8.02B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA withdrew a net $301M in Q3 2019, closing 128 positions and reducing 256 holdings. Its most notable exit was Celgene Corp, an estimated $70.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Nike worth $27.8M.
- Candriam SCA's largest Q3 2019 buy was Nike: 295,763 shares worth $27.8M.
- Candriam SCA added most to AbbVie in Q3 2019, an estimated $21.9M increase.
- Candriam SCA's biggest Q3 2019 reduction was Biogen, cutting an estimated $43.3M.
- Candriam SCA fully exited Celgene Corp in Q3 2019, selling an estimated $70.2M.
- Candriam SCA's ten largest holdings make up 21% of its $7.55B portfolio in Q3 2019.
- Candriam SCA opened 59 new positions and closed 128 in Q3 2019.
- Candriam SCA's portfolio value fell 5.9% quarter-over-quarter to $7.55B.
Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.